Etesevimab

埃特司韦单抗

Report date: 2026/02/10 20:00:22

Base Information

Drug NameEtesevimab
Drug Alias NameEtersivirLY-3832479LY-CoV016LY-CoV-016JS-016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoArgentina +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitute Of Microbiology Of Chinese Academy Of SciencesShanghai Junshi Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Union Biopharm Biosciences Co LtdEli Lilly And CompanyShanghai Junshi Biosciences Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsSevere Acute Respiratory Syndrome

Other Information

ATC CodeN/A
Related LinksDrugBank